Sun Pharmaceutical Industries, India's largest drugmaker by revenue, has launched its anti-baldness drug Leqselvi (deuruxolitinib) in the U.S. market following the settlement of a patent dispute with Incyte Corporation. Leqselvi is indicated for the treatment of severe alopecia areata and is now available for prescription in the United States. Clinical trials of the drug demonstrated rapid results, with some patients experiencing hair regrowth. The launch has positively impacted Sun Pharma's stock, which rose nearly 2% following the announcement.